Compare Stocks

AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company is also developing AB8939, a synthetic microtubule destabiliser for haematology indications. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.

Abattis Bioceuticals Corp. is a specialty biotechnology company. The Company aggregates, incubates, integrates and invests in the natural health product and botanical drug development industry. It operates through the segment of producing, licensing and marketing ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The Company, through its subsidiaries, develops and commercializes natural health (nutraceutical) products, and conducts research and development to create plant-based (botanical) intellectual property and ingredients for the pharmaceutical and bioceutical markets, among others. It offers products and services, such as botanical blends and formulas; cannabidiol ingredients; functional foods and beverages, and analytical services. It is focused on creating botanical formulations, medical marijuana and specialized health products for pain caused by inflammation, and mental ailments.

Colossus Minerals Inc. (Colossus) is a development-stage mining company. Colossus is focused on its Serra Pelada project into production. The Serra Pelada Project is located in the mineral prolific Carajas region in Para, Brazil, is host to high grade gold and platinum group metals deposit. The Company's three mineral properties in Brazil: the Serra Pelada Project, the Rio Cristalino Property and the Cutia Property. The Serra Pelada Project is the only material property of the Company. The Company's subsidiaries include Colossus Mineracao Ltda., Mineracao Fazenda Monte Belo Ltda., Serra Pelada - Companhia de Desenvolvimento Mineral, and Grifo Geologia e Participacoes Ltda. In January 2012, the Company acquired Cutia Property from Cooperativa Mista do Garimpeiro de Cutia.

IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.